SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series

被引：13
作者：
Zampieri, Mattia [1 ,2 ]
Argiro, Alessia [1 ,2 ]
Allinovi, Marco [1 ]
Perfetto, Federico [1 ,3 ]
Cappelli, Francesco [1 ,4 ]
机构：
[1] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Largo Brambilla 3, I-50134 Florence, Italy
[2] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy
[3] Careggi Univ Hosp, IV Internal Med Div, Florence, Italy
[4] Careggi Univ Hosp, Div Intervent Struct Cardiol, Cardiothoracovasc Dept, Florence, Italy
来源：
INTERNAL AND EMERGENCY MEDICINE | 2022年 / 17卷 / 04期
关键词：
Amyloidosis; SGLT2i; Heart failure; Diabetes; Empaglifozin; Dapagliflozin; Canagliflozin;
D O I：
10.1007/s11739-022-02944-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1243 / 1245
页数：3
相关论文
共 13 条
  • [1] SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series
    Mattia Zampieri
    Alessia Argirò
    Marco Allinovi
    Federico Perfetto
    Francesco Cappelli
    Internal and Emergency Medicine, 2022, 17 : 1243 - 1245
  • [2] SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices
    Mariani, Marco Valerio
    Lavalle, Carlo
    Palombi, Marta
    Pierucci, Nicola
    Trivigno, Sara
    D'Amato, Andrea
    Filomena, Domenico
    Cipollone, Pietro
    Laviola, Domenico
    Piro, Agostino
    Prosperi, Silvia
    Magliolo, Josefina
    Myftari, Vincenzo
    La Fazia, Vincenzo Mirco
    Severino, Paolo
    Chimenti, Cristina
    Badagliacca, Roberto
    Vizza, Carmine Dario
    ESC HEART FAILURE, 2025, : 2125 - 2133
  • [3] Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
    Tumminia, Andrea
    Graziano, Marco
    Vinciguerra, Federica
    Lomonaco, Andrea
    Frittita, Lucia
    PRIMARY CARE DIABETES, 2021, 15 (02) : 283 - 288
  • [4] Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
    Ito, Yuichiro
    Van Schyndle, James
    Nishimura, Takuya
    Sugitani, Toshifumi
    Kimura, Tomomi
    DIABETES THERAPY, 2019, 10 (02) : 549 - 562
  • [5] Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data
    Maria Klara Frey
    Henrike Arfsten
    Noemi Pavo
    Emilie Han
    Stefan Kastl
    Martin Hülsmann
    Mariann Gyöngyösi
    Jutta Bergler-Klein
    Cardio-Oncology, 7
  • [6] Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data
    Frey, Maria Klara
    Arfsten, Henrike
    Pavo, Noemi
    Han, Emilie
    Kastl, Stefan
    Huelsmann, Martin
    Gyoengyoesi, Mariann
    Bergler-Klein, Jutta
    CARDIO-ONCOLOGY, 2021, 7 (01)
  • [7] Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
    Brunton, Stephen
    Rozjabek, Heather M.
    Pilon, Dominic
    Lafeuille, Marie-Helene
    Kamstra, Rhiannon
    Wynant, Willy
    Bookhart, Brahim K.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1607 - 1614
  • [8] Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
    Tabella, Erika
    Correale, Michele
    Alcidi, Gianmarco
    Pugliese, Rosanna
    Ioannoni, Sara
    Romano, Matteo
    Palmieri, Gianpaolo
    Di Biase, Matteo
    Brunetti, Natale Daniele
    Iacoviello, Massimo
    CLINICS AND PRACTICE, 2023, 13 (05) : 1015 - 1024
  • [9] Prevalence of cardiac abnormalities and heart failure in unselected out-patients with type 2 diabetes mellitus and associated clinical factors: Real-world evidence from an Indian registry
    Rajput, Rajesh
    Mohan, J. C.
    Sawhney, J. P. S.
    Dalal, Jamshed
    Mullasari, Ajit
    Vasnawala, Hardik
    Kumar, Amit
    Hs, Bharath
    Sarda, Shital
    INDIAN HEART JOURNAL, 2023, 75 (06) : 436 - 442
  • [10] Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
    Kosiborod, Mikhail
    Birkeland, Kare I.
    Cavender, Matthew A.
    Fu, Alex Z.
    Wilding, John P.
    Khunti, Kamlesh
    Holl, Reinhard W.
    Norhammar, Anna
    Jorgensen, Marit E.
    Wittbrodt, Eric T.
    Thuresson, Marcus
    Bodegard, Johan
    Hammar, Niklas
    Fenici, Peter
    DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1983 - 1987
12